DBV Technologies (DBV) AI Stock Analysis

• Market Cap: €470.02M
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: N/A
• EPS Growth: 3.09%
• Country: FR
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 179,827,910
• 10 Day Avg. Volume: 2,165,856
• 30 Day Avg. Volume: 1,121,838
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 15.24
• P/FCF Ratio: -0.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €6.00
• Price Target Upside: 140.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: ―

DBV Technologies' overall stock score reflects significant financial challenges, with declining revenues and negative profitability as major concerns. The technical analysis indicates positive momentum, but the unfavorable valuation due to negative earnings and lack of dividend yield weighs heavily. Strategic restructuring is necessary to address these issues and improve the financial outlook.

DBV Technologies Business Overview & Revenue Model

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

How the Company Makes Money

DBV Technologies generates revenue primarily through licensing agreements and collaborations with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific clinical, regulatory, or commercial goals, and royalties on future product sales if the products are successfully brought to market. Additionally, as DBV Technologies is still in the clinical development stage for its lead product candidates, it may also receive funding through government grants, research subsidies, and potential investments from private investors to support its ongoing research and development efforts.

DBV Technologies Financial Statement Overview

Summary

DBV Technologies faces significant financial hurdles with declining revenues, negative profitability, and cash flow challenges. While the debt level is manageable, the ongoing net losses and reliance on financing pose risks. Strategic changes are required to improve financial health and stabilize the company’s operations.

Income Statement

DBV Technologies shows a challenging financial position with negative profitability metrics. TTM (Trailing-Twelve-Months) revenue has declined significantly compared to the previous year, resulting in negative EBIT and EBITDA margins indicating operational inefficiencies. The net profit margin is deeply negative due to substantial net losses, reflecting a need for strategic restructuring.

Balance Sheet

The balance sheet reflects a mixed position. The debt-to-equity ratio is modest, indicating manageable leverage. However, the company’s equity has decreased over time, and the equity ratio is low, suggesting potential risk in asset financing. The return on equity remains negative due to ongoing net losses, highlighting profitability issues.

Cash Flow

Cash flows are under pressure with a negative free cash flow growth rate. Operating cash flow is negative, exceeding net income losses, indicating cash management challenges. The company has been relying on external financing to support operations, which could be unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.26M	4.15M	15.73M	4.80M	5.71M	0.00
Gross Profit	-3.02M	4.15M	15.73M	-15.50M	-3.57M	-18.82M
EBITDA	-118.37M	0.00	-87.46M	-76.68M	-79.77M	-162.74M
Net Income	-124.99M	-113.92M	-72.73M	-96.30M	-97.81M	-195.68M
Balance Sheet
Total Assets	110.50M	65.66M	182.99M	246.50M	146.72M	333.87M
Cash, Cash Equivalents and Short-Term Investments	69.84M	32.46M	141.37M	209.20M	77.30M	240.80M
Total Debt	0.00	7.80M	6.55M	4.15M	9.74M	40.63M
Total Liabilities	57.64M	38.27M	42.80M	52.00M	47.45M	81.87M
Stockholders Equity	52.85M	27.39M	140.19M	194.50M	99.27M	252.01M
Cash Flow
Free Cash Flow	-98.30M	-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
Operating Cash Flow	-98.26M	-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
Investing Cash Flow	139.00K	-757.00K	-808.00K	-100.00K	-433.00K	―
Financing Cash Flow	117.80M	587.00K	6.77M	194.10M	274.00K	183.40M

DBV Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DBV, the sentiment is Positive. The current price of 2.5 is above the 20-day moving average (MA) of 2.45, above the 50-day MA of 2.38, and above the 200-day MA of 1.69, indicating a bullish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 53.44 is Neutral, neither overbought nor oversold. The STOCH value of 36.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DBV.

DBV Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNG	54 Neutral	€195.31M	-5.30	―	―	111.76%	-22.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALSEN	51 Neutral	€102.80M	-3.66	-40.00%	―	―	10.87%
DBV	50 Neutral	€470.02M	-2.76	-241.12%	―	―	3.09%
NANO	49 Neutral	€832.03M	-23.55	―	―	―	―
OSE	49 Neutral	€128.53M	-3.62	-52.76%	―	-96.92%	-175.84%
IPH	47 Neutral	€153.37M	―	-271.32%	―	-75.86%	-30.54%